About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Poor sleep quality may be linked to higher mortality for adults on hemodialysis, data show. “Impaired sleep and sleep-related ...

In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.

In a Korean national study, osteoporotic fracture was associated with higher risks for graft failure and death among kidney transplant recipients. Bone fracture from osteoporosis in kidney transplant ...

People hospitalized for a severe bout of COVID-19 are far from in the clear after they've recovered enough to return home ...

The Department of Medicine Nephrology Service at Womack Army Medical Center are pushing the limits of what can be done to ...

A new study from Karolinska Institutet has found that people with chronic kidney disease (CKD) are significantly more likely ...

The five stages of chronic kidney disease (CKD) indicate how well the kidneys are working, ranging from stage 1 (mild kidney ...

Explore the efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney ...

An early-phase trial found that a personalized vaccine targeted and destroyed cancer cells in nine patients with advanced kidney cancer, effectively wiping out the disease and keeping it at bay ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

There used to be no specific treatments for heart failure with preserved ejection fraction, but recent clinical trials show ...